선택적 제품 분석
허용하는 경우 개인정보 보호를 고려한 제한적 분석을 사용해 어떤 리서치 여정이 효과적인지 파악합니다. 광고 추적기나 세션 녹화는 사용하지 않습니다. 환경설정에서 이 선택을 변경할 수 있습니다. 자세한 내용은 개인정보 처리방침.
Cognizant Technology Solutions Corporation's published Strong Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $27.5B | |
|---|---|---|
| Revenue (ttm) | 21.6B | |
| Net income (ttm) | 2.2B | |
| EPS (ttm) | $4.64 | |
| Shares out | 450.4M | |
| P/E (trailing) | 14.3x | |
| P/E (forward) | 9.4x | |
| Dividend | $1.32 (2.00%) | |
| Volume | 5,107,961 | |
| Beta | 0.85 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $18.51B | $19.43B | $19.35B | $19.74B | $21.11B | +3.3% |
| Gross profit | $6.90B | $6.98B | $6.69B | $6.78B | $7.12B | +0.8% |
| Operating income | $2.83B | $2.97B | $2.69B | $2.89B | $3.39B | +4.6% |
| Net income | $2.14B | $2.29B | $2.13B | $2.24B | $2.23B | +1.1% |
| EPS (diluted) | $4.05 | $4.41 | $4.21 | $4.51 | $4.56 | +3.0% |
| EBITDA | $3.41B | $3.60B | $3.38B | $3.53B | $4.17B | +5.2% |
| R&D | — | — | — | — | — | — |
| SG&A | $3.50B | $3.44B | $3.25B | $3.22B | $3.24B | -1.9% |
Recent company headlines from major financial publishers.
The base case represents the modal expected trajectory, reflecting steady execution across multi-year enterprise contracts, mid-single-digit top-line growth, and modest margin expansion driven by delivery automation. Regulated domain stability in Health Sciences and Financial Services sustains double-digit operating margins and robust cash generation, while ongoing share repurchases support diluted earnings compounding. This path establishes Fair value at $94.37 with an assigned probability of 60.0%, representing 62.2% upside from $58.17.
In the bull case, enterprise digital transformation spending re-accelerates as large corporate clients aggressively deploy generative AI workflows and modern cloud architecture. Health Sciences and Financial Services expand above historical mid-single-digit rates, and European market share gains accelerate across the United Kingdom and Continental Europe. Operational leverage and delivery automation expand operating margins, while disciplined free cash flow conversion accelerates share count retirement. This trajectory targets $116.80 with an assigned probability of 20.0%, offering an implied return of 100.8% from $58.17.
| Ke ↓ / g → | 2.0% | 2.3% | 2.5% | 2.8% | 3.0% |
|---|---|---|---|---|---|
| 8.0% | $103 | $105 | $109 | $112 | $116 |
| 8.5% | $96.0 | $98.3 | $101 | $104 | $107 |
| 9.0% | $90.2 | $92.2 | $94.4 | $96.7 | $99.2 |
| 9.5% | $85.3 | $87.0 | $88.8 | $90.7 | $92.8 |
| 10.0% | $80.9 | $82.4 | $83.9 | $85.5 | $87.3 |
Upcoming earnings date and setup when available.
매월 발행된 리서치 판이 부여한 등급입니다. 등급은 분석 시점의 가격을 공정 가치와 비교한 것이며, 판단이 맞았는지에 대한 기록이 아닙니다.
| 연도 | 1월 | 2월 | 3월 | 4월 | 5월 | 6월 | 7월 | 8월 | 9월 | 10월 | 11월 | 12월 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |